Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced today that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently-hired Commercial Director for the Western U.S. The option to purchase 17,000 shares of common stock was granted on May 5, 2026, with an exercise price of $3.20 per share, equal to the closing price on that date. This grant was made as an inducement material to Mr. Keefe's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
The option vests over four years: one-quarter on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued service. The option carries a 10-year term and is governed by an inducement stock option agreement. This move underscores Aclarion's commitment to expanding its commercial team as demand for its Nociscan platform accelerates, supported by triple-digit growth in utilization.
Nociscan is a SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine using magnetic resonance spectroscopy (MRS) data, proprietary signal processing, biomarkers, and augmented intelligence algorithms. By providing critical insights into the location of chronic low back pain, Nociscan aims to improve treatment success rates. The company's expansion of its commercial presence in the Western U.S. reflects increasing adoption of the technology.
“We are pleased to welcome Daniel Keefe to our commercial leadership team,” said a company spokesperson. “His experience will be instrumental as we continue to scale our operations and meet the growing demand for Nociscan.” The appointment comes as Aclarion focuses on penetrating the chronic low back pain market, a condition affecting millions worldwide.
For more information about Aclarion and Nociscan, visit www.aclarion.com.
This press release contains forward-looking statements regarding the company's expectations about future results and performance, including statements about increasing demand for Nociscan. These statements are subject to risks and uncertainties discussed in the company's filings with the Securities and Exchange Commission. Aclarion undertakes no obligation to update forward-looking statements.
